This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner
by Zacks Equity Research
Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.
Three Reasons to Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
Centene (CNC) to Continue Serving Kansas' Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.
Merit Medical (MMSI) to Expand Product Suite Via New Launch
by Zacks Equity Research
Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales
by Zacks Equity Research
Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
by Zacks Equity Research
Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.
Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
by Zacks Equity Research
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Three Reasons to Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights Hasbro, Brinker International, DaVita, Leidos Holdings and Allstate
by Zacks Equity Research
Hasbro, Brinker International, DaVita, Leidos Holdings and Allstate have been highlighted in this Screen of The Week article.
5 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like HAS, EAT, DVA, LDOS and ALL are seeing price strength and have a high chance of carrying the momentum forward.
4 Must-Buy Momentum Stocks Banking on the Driehaus Strategy
by Tirthankar Chakraborty
DaVita (DVA), Minerals Technologies (MTX), Alphabet (GOOGL) and Garmin (GRMN) have been selected as the momentum picks for the day using the Driehaus strategy.
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Alcon (ALC) have performed compared to their sector so far this year.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.